Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on May 18, 2021 3:35pm
113 Views
Post# 33223609

RE:RE:RE:RE:RE:RE:RE:RE:Dual approach of Tesamorelin…

RE:RE:RE:RE:RE:RE:RE:RE:Dual approach of Tesamorelin…My best guess is Leah was busy preparing Montreal-style smoked meat as the entire IR department having their daily picnic at Mount Royal Park?


SPCEO1 wrote: I would think any time one of your drugs is featured in a Nature article, that it would be worthy of a press release. I assume you don't get your article published in Nature unless you really have something noteworthy in the article. Can anyone think why TH would not draw attention to this article? 

scarlet1967 wrote: Tesamorelin has inhibiting effects on pro inflammatory proteins responsible for liver inflammation/fibrosis.

Bucknelly21 wrote:
scarlet1967 wrote:
Some details from this study so they are explaining the proteomic (studying proteins) and transcriptomic (studying molecules expressed from the genes) effect of tesamorelin a dual approach for the treatment of NAFL/NASH. Nothing new but they sum it up nicely and tied some loose ends (totality of data). I like the fact that they mentioned innovative treatment few times.
 
“Tesamorelin suppressed key angiogenic (blood vessel growth), fibrogenic (promoting the development of fibers) and pro-inflammatory mediators. CSF1 (gene), a regulator of monocyte (white blood cell that fight infections) recruitment and activation, may serve as an innovative therapeutic target for NAFLD in HIV.
Notably, compared to the general population, NAFLD has a more aggressive clinical course with a high frequency of nonalcoholic steatohepatitis (NASH) and fibrosis, and an accelerated rate of fibrosis progression among PLWH.
Within the tesamorelin-treated arm, reductions in plasma VEGFA (gene) and CSF1 correlated with a decline in NAS score. Furthermore, among tesamorelin-treated participants, reductions in TGFB1 (gene) and CSF1were associated with a decline in gene-level fibrosis score. 
Notably, among tesamorelin-treated participants, decreases in plasma levels of VEGFA and CSF1 correlated with a reduction in NAS score, whereas declines in TGFB1 and CSF1 were associated with a decrease in fibrosis-related gene score. 
Human and animal studies have shown hepatic upregulation of TGFB1 expression with NASH and fibrosis. Moreover, in a NASH mouse model, hepatocyte (liver cells)-specific TGFB receptor type II deficiency reduced hepatic steatosis, inflammation, hepatic stellate cell activation, and collagen deposition17. Given the role of TGFB1 in NAFLD, the decline in this growth factor with tesamorelin may contribute to its attenuation of NAFLD, and particularly fibrosis, progression in PLWH.
Taken together, in this focused proteomic analysis guided by a whole transcriptomic approach, we identified VEGFA, TGFB1, and CSF1 as novel proteins whose circulating levels were reduced by tesamorelin in association with a decline in NAFLD severity among PLWH with NAFLD. The current study extends our knowledge of the biologic actions of GH axis augmentation to encompass systemic changes in key angiogenic, fibrogenic, and pro-inflammatory factors that may underlie a tesamorelin response. Notably, among these proteins, CSF1 is a key regulator of monocyte recruitment and activation that has not been previously well studied in the context of NAFLD, but may serve as an innovative therapeutic target in this regard. Lastly, our data indicate that VEGFA, TGFB1, and CSF1 are candidate biomarkers for a tesamorelin response among PLWH with NAFLD, which should be explored in future studies.”
 
can someone break it down for us non science people 
 

 




<< Previous
Bullboard Posts
Next >>